A detailed history of Virtu Financial LLC transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Virtu Financial LLC holds 7,734 shares of CRSP stock, worth $316,629. This represents 0.02% of its overall portfolio holdings.

Number of Shares
7,734
Previous 9,945 22.23%
Holding current value
$316,629
Previous $537,000 32.4%
% of portfolio
0.02%
Previous 0.04%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 20, 2024

SELL
$44.62 - $62.75 $98,654 - $138,740
-2,211 Reduced 22.23%
7,734 $363,000
Q2 2024

Aug 09, 2024

SELL
$51.17 - $68.18 $2.75 Million - $3.67 Million
-53,797 Reduced 84.4%
9,945 $537,000
Q1 2024

May 20, 2024

BUY
$60.67 - $89.12 $1.99 Million - $2.93 Million
32,880 Added 106.54%
63,742 $4.35 Million
Q4 2023

Feb 26, 2024

BUY
$38.62 - $72.18 $663,723 - $1.24 Million
17,186 Added 125.67%
30,862 $1.93 Million
Q3 2023

Nov 14, 2023

SELL
$45.39 - $59.0 $585,848 - $761,513
-12,907 Reduced 48.55%
13,676 $621,000
Q2 2023

Jul 27, 2023

BUY
$43.47 - $67.77 $1.16 Million - $1.8 Million
26,583 New
26,583 $1.49 Million
Q3 2022

Nov 07, 2022

SELL
$61.1 - $83.78 $2.6 Million - $3.56 Million
-42,534 Reduced 75.53%
13,777 $900,000
Q2 2022

Aug 09, 2022

BUY
$43.23 - $73.83 $1.47 Million - $2.5 Million
33,910 Added 151.38%
56,311 $3.42 Million
Q1 2022

May 17, 2022

BUY
$53.19 - $79.24 $613,014 - $913,240
11,525 Added 105.97%
22,401 $1.41 Million
Q4 2021

Feb 17, 2022

BUY
$70.09 - $111.29 $762,298 - $1.21 Million
10,876 New
10,876 $824,000
Q2 2021

Sep 17, 2021

SELL
$100.84 - $161.89 $2.12 Million - $3.4 Million
-21,000 Closed
0 $0
Q1 2021

May 19, 2021

BUY
$110.72 - $210.04 $1.73 Million - $3.29 Million
15,648 Added 292.38%
21,000 $2.56 Million
Q1 2018

May 14, 2018

BUY
$23.52 - $58.17 $125,879 - $311,325
5,352 New
5,352 $245,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.19B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Virtu Financial LLC Portfolio

Follow Virtu Financial LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtu Financial LLC with notifications on news.